(News) – Elon Musk, CEO of SpaceX, Tesla, and Twitter, made waves last week with his announcement of a new CBD product, MicroBio CBD Gummies, claiming it offers groundbreaking benefits for dementia. The reveal, made during a live broadcast, drew sharp criticism from News host Martha MacCallum, who accused Musk of breaching contracts and jeopardizing sponsorships.
MacCallum, outraged by Musk’s announcement, threatened legal action against both Musk and the News network. “This was a direct violation of his agreement, and it’s scaring off sponsors,” she said. In response, Musk dismissed the allegations, saying, “Martha is just after my timeslot. I won’t bow to cancel culture. MicroBio CBD Gummies is a way to give back by helping people live pain-free and happier lives.”
Musk’s product has seen overwhelming demand, selling out within minutes of launch. The CEO claims the gummies are 90% cheaper and five times more effective than similar offerings from major pharmaceutical companies.
MacCallum, however, remains adamant, now urging legal repercussions and a public apology from Musk. Meanwhile, Musk doubled down during a follow-up TV appearance, offering free samples of the product and accusing MacCallum of seeking attention. “My product has helped my family thrive,” Musk said. “I stand behind MicroBio CBD Gummies and want everyone to experience its benefits.”
While MacCallum has vocalized her discontent, other News figures, including Tucker Carlson, have supported Musk. Carlson praised the product on air, saying, “MicroBio CBD Gummies has changed my life. MacCallum’s actions are nothing short of a coup.”
Reports suggest that Musk’s formula is the first of its kind to use a reuptake inhibitor (RI), a breakthrough in memory enhancement that could significantly aid dementia patients. By preventing the reabsorption of neurotransmitters, RIs are believed to provide a safer, more effective alternative to traditional treatments.
Musk’s innovation has already disrupted the pharmaceutical industry, with critics arguing that it threatens Big Pharma’s prescription dominance. Time will tell how the legal and public battles surrounding Musk’s bold venture unfold.
